Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration

Drug Delivery

Volumn 22, Issue 6, 2015, Pages 691-700

  Gaba, Bharti ^a   Fazil, Mohammad ^a   Ali, Asgar ^a   Baboota, Sanjula ^a   Sahni, Jasjeet K ^b   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

^b KHALSA COLLEGE   (India)

Author keywords

Bioavailability; biocompatibility; hydrophilic drugs; loading capacity; nano structured lipid carriers

Indexed keywords

DOMPERIDONE; GLIPIZIDE; LIPID; MEVINOLIN; NANOCARRIER; NANOMATERIAL; SAQUINAVIR; SPIRONOLACTONE; SURFACTANT; TAMOXIFEN; TESTOSTERONE UNDECANOATE; THYMOQUINONE; VINPOCETINE; DRUG CARRIER;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; HYDROPHILICITY; PRIORITY JOURNAL; REVIEW; TEMPERATURE; BIOAVAILABILITY; CHEMISTRY; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; INTESTINAL ABSORPTION; LIPIDS; NANOSTRUCTURES; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 84941265234     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.898110     Document Type: Review

References (83)

1. Abdelwahab SI, Sheikh BY, Taha MME, et al. (2013). Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int J of Nanomedicine 8: 2163-72
2. Andrysek T. (2003). Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine. Mol Immunol 39: 1061-5
3. Andrysek T. (2006). Excipients and their role in absorption: Influencing bioavailability of cyclosporine by triglycerides and polyglycerol esters. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150: 227-33
4. Beloqui A, Solinis MA, Gascon AR, et al. (2012). Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Rel 166: 115-23
5. Beloqui A, Solinis MA, Dalgado A, et al. (2013). Fate of nanostructured lipid carriers (NLCs) following the oral route:design, pharmacokinetics and biodistribution. J Microencapsul 31: 1-8
6. Bondi ML, Azzolina A, Craparo EF, et al. (2007). Novel cationic solid-lipid NPs as non-viral vectors for gene delivery. J Drug Target 15: 295-301
7. Bummer PM. (2004). Physical chemical considerations of lipid based oral drug delivery solid lipid NPs. Critical Rev. Thera Drug Carrier Sys 21: 1-19
8. Bunjes H. (2010). Lipid NPs for the delivery of poorly water-soluble drugs. J Pharm Pharmcol 62: 1637-45
9. Cavalli R, Caputo O, Marengo E, et al. (1998). The effect of the components of microemulsions on both size and crystalline structure of solid lipid NPs (SLN) containing a series of model molecules. Pharmazie 53: 392-6
10. Charcosset C, El-Harati A, Fessi H. (2005). Preparation of solid lipid NPs using a membrane contractor. J Control Release 108: 112-20
11. Charman WN, Porter CJ, Mithani S, Dressman JB. (1997). Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharma Sci 86: 269-82
12. Charman WN. (2000). Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharma Sci 89: 967-8
13. Chen CC, Tsai TH, Huang ZR, Fang JY. (2010). Effects of lipophilic emulsifiers on gthe oral administration of lovastatin from nanostructred lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74: 474-82
14. Cortesi R, Esposito E, Luca G, Nastruzzi C. (2002). Production of lipospheres as carriers for bioactive compounds. Biomaterials 23: 2283-94
15. Das S, Chaudhury A. (2011). Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 12: 62-76
16. Das S, Ng WK, Tan RBH. (2012). Are nanostructured lipid carriers (NLCs) better than solid lipid NPs (SLNs): development, characterization and comparative evaluations of Clotimazole-loaded SLNs and NLCs? Eu J of Pharm Sci 47: 139-51
17. Davidson MH, Lukacsko P, Sun JX, et al. (2002). A multiple-dose pharmacodynamis, safety and pharmacokinetic comparison of extended and immediate-release formulations of lovastatin. Clin Ther 24: 112-25
18. Florence AT. (2005). Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today Technol 2: 75-81
19. Foye WO, Lemke TL, Williams DA. (2007). Foyes principle of medicinal chemistry, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins
20. Gasco MR. (1993). Method for producing solid lipid microspheres having a narrow size distribution patent US5250236
21. Hard GC, Iatropoulos MJ, Jordan K, et al. (1993). Major difference in the hepatocarcinogenicity and DNAadduct forming ability between toremifene and tamoxifen in female Crl: CD (BR) rats. Cancer Res 53: 4534-41
22. Hauss DJ. (2007). Oral lipid-based formulations. Adv Drug Deliv Rev 59: 667-76
23. Heurtault B, Salunier P, Pech B, et al. (2002). A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 19: 875-80
24. Hu FQ, Jiang SP, Du YZ, et al. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 45: 167-73
25. Hu FQ, Jiang SP, Du YZ, et al. (2006). Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm 314: 83-9
26. Hu FQ, Yuan H, Zhang HH, Fang M. (2002). Preparation of solid lipid NPs with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 239: 121-8
27. Huang ZR, Hua SC, Yang YL, Fang JY. (2008). Development and evaluation of lipid NPs for camptothecin delivery: a comparison of solid lipid NPs, nanostructured lipid carriers and lipid emulsion. Acta Pharmacol Sin 29: 1094-102
28. Igartua M, Saulnier P, Heurtault B, et al. (2002). Development and characterization of solid lipid NPs loaded with magnetite. Int J Pharm 233: 149-57
29. Iqbal MA, Md S, Sahni JK, et al. (2012). Nanostructured lipid Carrier System: recent advances in drug delivery. J Drug Target 20: 813-30
30. Jain NK, Ram A. (2011). Development and characterization of nanostructred lipid carriers of oral hypoglycemic agent selection of surfactants. Int J Pharma Sci Rev Res 7: 125-130
31. Jenning V, Lippacher A, Gohla SH. (2002). Medium scale production of solid lipid NPs (SLN) by high pressure homogenization. J Microencapsul 19: 1-10
32. Jenning V, Schafer-Korting M, Gohla S. (2000). Vitamin A-loaded solid lipid NPs for topical use: drug release properties. J Control Release 66: 115-26
33. Kakkar V, Singh S, Singla D, Kaur IP. (2011). Exploring solid lipid NPs to enhance the oral bioavailability of curcumin. Mol Nut Food Res 55: 495-503
34. Keck C, Muchow M. (2009). Nanonized testosterone formulations for improved bioavailability. EP20090003370
35. Kohn FM, Schiil WB. (2003). A new oral testosterone undecanoate formulation. World J Urol 21: 311-15
36. Li R, Eun JS, Lee MK. (2011). Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid NPs after intravenous administration. Archives of Pharmacal Research 34: 331-7
37. Limayem BI, Charcosset C SS, Fessi H. (2006). Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use. Int J Pharm 325: 124-31
38. Luck M, Pistel KF, Li YX, et al. (1997). Plasma protein adsorption on biodegradable microspheres consisting of poly(-lactide-co-glycolide), poly(-lactide) or Aba triblock copolymers containing poly(oxyethylene) Influence of production method and polymer composition. J ControlRelease 55: 107-20
39. Luo CF, Yuan M, Chen MS. (2011). Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid NPs following oral administration. Int J Pharm 410: 138-44
40. Madisheti SK, Palem CR, Gannu R, et al. (2010). Development of domperidone bilayered matrix type transdermal patches: physicochemical in vitro and ex vivo characterization. Daru 18: 221-9
41. Mauludin R, Muller RH, Keck CM. (2009). Development of an oral rutin nanocrystal formulation. Int J Pharm 370: 202-09
42. McVie JG, Simonetti GP, Stevenson D, et al. (1986). The bioavailability of tamoplex (tamoxifen). Part 1 A pilot study. Methods Find Exp Clin Pharmacol 8: 505-12
43. Mehnert W, Mader K. (2001). Solid lipid NPs: Production, characterization and applications. Adv Drug Deliv Rev 47: 165-96
44. Muchow M, Maincent P, Muller RH, Keck CM. (2011). Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharma 37: 8-14
45. Muller R. (2000a). Extended patent on the basis of (11), PCT application PCT/EP00/04112, (2000)
46. Muller R, Mader K, Gohla S. (2000b). Solid lipid NPs (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 50: 161-77
47. Muller RH, Dingler A. (1998). The next generation after the liposomes: solid lipid NPs (SLNTM) as dermal carrier in cosmetics. Eurocosmetics 7/8: 19-26
48. Muller RH, Keck CM. (2004). Challenges and solutions for the delivery of biotech drugs-A review of drug nanocrystal technology and lipid NPs. J Biotech 113: 151-70
49. Muller RH, Maassen S, Weyhers H, Mehnert W. (1996). Phagocytic uptake and cytotoxicity of solid lipid NPs (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Targeting 4: 161-70
50. Muller RH, Radtke M, Wissing SA. (2002a). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242: 121-8
51. Muller RH, Radtke M, Wissing SA. (2002b). Solid lipid NPs (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54: S131-55
52. Muller RH, Radtke M, Wissing SA. (2004). Solid lipid NPs and nanostructured lipid carriers. Encyclopedia of nanoscience and nanotechnology. CA: American Scientific Publishers, 43-56
53. Muller RH, Souto EB, Goppert T, et al. (2005). Production of biofunctionalized solid lipid nanoparticles for site-specific drug delivery. In: Nanotechnologies for the life sciences biological and pharmaceutical nanomaterials, 291-307
54. Muller RH, Wissing SA. (2003). Lipopearls for topical delivery of active compounds and controlled release. Modified-release drug delivery systems. New York: Marcel Dekker Inc
55. ODriscoll CM, Griffin BT. (2008). Biopharmaceutical challenges associated with drugs with low aqueous solubility-the potential impact of lipid based formulations. Adv Drug Deliv Rev 60: 617-24
56. Olbrich C, Gessner A, Kayser O, Muller RH. (2002). Lipid-drug-conjugate (LDC) NPs as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Targ 10: 387-96
57. Overdiek HW, Merkus FW. (1987). The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interac 5: 273-302
58. Parvez S, Tabassum H, Rehman H, et al. (2006). Catechin prevents tamoxifen-induced oxidative stress and biochemical perturbations in mice. Toxicology 225: 109-18
59. Radtke M, Souto EB, Muller RH. (2005). Nanostructured Lipid Carriers: a novel generation of solid lipid drug carriers. Pharm Technol Eur 17: 45-50
60. Rawat M, Singh D, Saraf S. (2006). Nanocarriers: promising Vehicle for Bioactive Drugs. Biol Pharm Bull 29: 1790-8
61. Rawat MK, Jain A, Singh S. (2011). In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid NPs after oral administration to rats. J Pharma 100: 2406-17
62. Ruktanonchai U, Bejrapha P, Sakulkhu, et al. (2009). Physicochemical characteristics, cytotoxicity and antioxidant activity of three lipid nanoparticulate formulation of alpha-lipoic acid. AAPS Pharm Sci Tech 10: 227-34
63. Schafer-Korting M, Mehnert W, Korting HC. (2007). Lipid NPs for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 59: 427-43
64. Schubert MA, Muller-Goymann CC. (2003). Solvent injection as a new approach for manufacturing lipid NPs-evaluation of the method and process parameters. Eur J Pharm Biopharm 55: 125-31
65. Severino P, Andreani T, Macedo AS, et al. (2011). Current state-of-art and new trends on lipid nps (sln and nlcs) for oral drug deliver. J Drug Del 2012: 1-10
66. Shahgaldian P, Da SE, Coleman AW, et al. (2003). Para-acyl-calix-arene based solid lipid NPs (SLNs): a detailed study of preparation and stability parameters. Int J Pharm 253: 23-38
67. Shete H, Chatterjee S, De A, Patravale V. (2013). Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm 454: 584-92
68. Shin SC, Choi JS, Li X. (2006). Enhanced bioavailability of tamoxifen after oraladministration of tamoxifen with quercetin in rats. Int J Pharm 313: 144-9
69. Sjostrom B, Kaplun A, Talmon Y, Cabane B. (1995). Structures of NPs prepared from oil-in-water emulsions. Pharm Res 12: 39-48
70. Souto EB, Doktorovova S, Boonme P. (2011). Lipid nanocarriers-based semisolids: review on materials and end product formulations. J Drug Del Sci Tech 21: 43-54
71. Souto EB, Muller RH. (2010). Lipid NPs: effect on bioavailability and pharmacokinetic changes. Handbook Exp Pharmacol 197: 115-41
72. Souto EB, Wissing SA, Barbosa CM, Muller RH. (2004a). Comparative study between the viscoelastic behaviors of different lipid nanoparticle formulations. J Cosmet Sci 55: 463-71
73. Stecova J, Mehnert W, Blaschke T, et al. (2007). Cyproterone acetate loading to lipid NPs for topical acne treatment: particle characterization and skin update. Pharma Res 24: 991-1000
74. Sweetman SC. (2007). Matrindale the complete drug reference. London, UK: Pharmaceutical press
75. Teeranachaideekul V, Muller RH, Junyaprasert VB. (2007). Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int J Pharm 340: 198-206
76. Thatipamula R, Palem C, Gannu R, et al. (2011). Formulation and in vitro characterization of domperidone solid lipid NPs and nanostructured lipid carriers. Daru 19: 23-32
77. Trotta M, Debernardi F, Caputo O. (2003). Preparation of solid lipid NPs by a solvent emulsification-diffusion technique. Int J Pharm 257: 153-60
78. Tukker JJ, Blankenstein MA, Nortier JW. (1986). Comparison of bioavailability inman of tamoxifen after oral and rectal administration. J Pharm Pharmacol 38: 888-92
79. Weyhers H, Ehlers S, Hahn H, et al. (2006). Solid lipid NPs (SLN)-effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 61: 539-44
80. Wissing SA, Kayser O, Muller RH. (2004). Solid lipid NPs for parenteral drug delivery. Adv Drug Deliv Rev 56: 1257-72
81. Years FP, Ying L, Shan W, et al. (2010). Nanostructured lipid carrier, preparation method and application. CN(201010224865)
82. Yuan H, Wang LL, Du YZ, et al. (2007). Preparation and characteristics of nanostructured lipid carriers for control-sssreleasing progesterone by melt emulsification. Colloids Surf B Biointerfaces 60: 174-9
83. Zhuang CY, Li N, Wang M, et al. (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharma 394: 179-85